The Chemical Biological Medical Systems Joint Project Management Office rapidly provides the Warfighter with safe, robust, affordable medical countermeasures against a broad spectrum of Chemical Biological Radiological Nuclear (CBRN) threats. Established in 2002 (chartered in 2003), CBMS is a part of the Joint Program Executive Office for Chemical & Biological Defense and serves a key role in the Department of Defense's comprehensive national strategy to counter the threat of CBRN weapons of mass destruction.

## OUR VISION

A U.S. military force that is fully sustained to fight and win in any CBRN battlespace worldwide.

## OUR MISSION

To deliver safe, effective and robust medical products that protect U.S. forces against validated CBRN threats. We apply government and industry best practices to develop or acquire FDA-approved products within rigorously managed cost, schedule and performance constraints.


Chemical Biological Medical Systems
Frederick, Maryland
301-619-7400
CBMSINFO@AMEDD.ARMY.MIL


CBMS
CHEMICAL BIOLOGICAL MEDICAL SYSTEMS

# CHEMICAL BIOLOGICAL MEDICAL SYSTEMS

CBRN MEDICAL COUNTERMEASURES

PROTECTING THE WARFIGHTER & THE NATION

# CBMS: PROTECTING THE WARFIGHTER & THE NATION

The Chemical Biological Medical Systems (CBMS) Joint Project Management Office is responsible for research, development, acquisition, fielding, and life cycle management of U.S. Food and Drug Administration (FDA) approved/cleared medical systems for protection, treatment, and diagnostic capabilities against Chemical Biological Radiological Nuclear (CBRN) threat agents. All CBRN medical countermeasures are approved by and regulated through the FDA. CBMS aggressively explores opportunities to partner with other government agencies, industry, academia, and allied countries for all CBRN medical countermeasure efforts.

The CBMS product portfolio includes products spanning the entire acquisition life cycle. CBMS is composed of a headquarters and three Joint Product Management Offices: The Joint Vaccine Acquisition Program, the Medical Identification and Treatment Systems, and Biosurveillance (provisional).

## CBRN MEDICAL COUNTERMEASURES

The CBMS-Joint Vaccine Acquisition Program (CBMS-JVAP) develops, produces, and stockpiles FDA-licensed vaccine systems to protect the Warfighter against biological agents. CBMS-JVAP consolidates the Department of Defense's (DoD) efforts for advanced development, testing, FDA licensing, production, and storage of biological defense vaccines.

Air Force Medical Technician prepares the Anthrax vaccine
*Photo Credit: DoD Defenselink.mil.*
*Photographer: Senior Airman Kasey Zickmunc, USAF*

CBMS-JVAP's impressive portfolio of fielded products to the Warfighter include the Anthrax Vaccine Adsorbed (AVA) Biothrax©, The Smallpox vaccine ACAM2000©, and the Vaccinia Immune Globulin, a treatment for rare adverse reactions to the smallpox vaccine. CBMS-JVAP's advanced development portfolio includes the plague vaccine, botulinum toxin vaccine, and filovirus vaccine.



Army Medical Technician administers the Smallpox vaccine
*Photo Credit: USAMRIID and CBMS*

The CBMS-Medical Identification and Treatment Systems (CBMS-MITS) provides the Warfighter and the Nation with robust, affordable FDA-approved lifesaving medical countermeasure drug capabilities against chemical, biological, radiological, and nuclear (CBRN) threats. CBMS-MITS serves as the life cycle product manager for the following fielded products: Convulsant Antidote for Nerve Agents (CANA), Antidote Treatment Nerve Agent Autoinjector (ATNAA), and Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP). CBMS-MITS advanced development efforts include Bioscavenger, Advanced Anticonvulsant System (AAS), Improved Nerve Agent Treatment System (INATS), Inhalation Atropine (IA), and Medical Radiation Countermeasures (MRADC). A future advanced development effort, the Centrally-Acting Nerve Agent Treatment System (CANATS), is preparing for transition to MITS from the technology base.

Army soldier demonstrates use of Soman Nerve Agent Pre-treatment Pyridostigmine (SNAPP) - an FDA-approved drug that protects against the chemical warfare agent soman
*Photo Credit: CBMS*

Warfighter demonstrates use of Antidote Treatment Nerve Agent Autoinjector (ATNAA) - post exposure treatment administered for nerve agent toxicity
*Photo Credit: CBMS*

CBMS-Biosurveillance (BSV) develops and integrates state-of-the-art chemical, biological, radiological, and nuclear technologies to enable early warning, identification, and situational awareness of potential global health threats. CBMS-BSV's portfolio includes the Critical Reagents Program (CRP) and two diagnostic programs: The Joint Biological Agent Identification and Diagnostic System (JBAIDS) and the Next Generation Diagnostic System (NGDS).

Joint Biological Agent Identification and Diagnostic System (JBAIDS)
*Photo Credit: CBMS*

The CRP features a collection of world-class reagents and assays used throughout the biodefense community world-wide, including interagency and international partners. These products have been verified against the strictest International Organization for Standardization guidelines and industry leading quality assurance practices. The CRP products include robust pathogen and reference material repositories, genomic materials, antigens, antibodies, polymerase chain reaction assays, electrochemiluminescence assays, system reagents, and lateral flow immunoassays.

The JBAIDS program exhibits the only FDA 510(k)-cleared tests in the DoD for Anthrax, Plague, Tularemia, and Influenza (A/H5) and over 70 pre-emergency use authorizations ready for deployment upon declaration of a national emergency. The NGDS will bring innovative technologies and advances in diagnostics to the Warfighter where and when they need them.



Lab technician performs test on Critical Reagent Program's (CRP) Hand Held Assays - a critical component of biological warfare agent detection and medical diagnostic systems
*Photo Credit: CBMS*